Moderna, Inc. (NASDAQ:MRNA) Director Sells $1,767,000.00 in Stock

Moderna, Inc. (NASDAQ:MRNA) Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, July 24th. The stock was sold at an average price of $117.80, for a total value of $1,767,000.00. Following the sale, the director now directly owns 2,239,015 shares of the company’s stock, valued at $263,755,967. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Noubar Afeyan also recently made the following trade(s):

• On Wednesday, July 17th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $122.84, for a total value of $1,842,600.00.
• On Wednesday, July 10th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $117.08, for a total value of $1,756,200.00.
• On Wednesday, June 26th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $127.22, for a total value of $1,908,300.00.
• On Tuesday, June 11th, Noubar Afeyan sold 202,832 shares of Moderna stock. The shares were sold at an average price of $148.34, for a total value of $30,088,098.88.
• On Wednesday, June 5th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $151.25, for a total value of $2,268,750.00.
• On Wednesday, May 29th, Noubar Afeyan sold 20,000 shares of Moderna stock. The shares were sold at an average price of $145.08, for a total value of $2,901,600.00.
• On Wednesday, May 22nd, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $157.57, for a total value of $2,363,550.00.
• On Wednesday, May 15th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $127.32, for a total value of $1,909,800.00.
• On Wednesday, May 8th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $121.68, for a total value of $1,825,200.00.
• On Wednesday, May 1st, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $110.92, for a total value of $1,663,800.00.

Moderna Stock Performance

MRNA traded up $1.71 during trading on Friday, hitting $122.11. 1,884,844 shares of the stock were exchanged, compared to its average volume of 4,016,060. The firm has a market capitalization of $46.80 billion, a P/E ratio of -7.79 and a beta of 1.66. Moderna, Inc. has a 1-year low of $62.55 and a 1-year high of $170.47. The stock has a fifty day moving average price of $134.57 and a two-hundred day moving average price of $115.01. The company has a quick ratio of 3.91, a current ratio of 4.03 and a debt-to-equity ratio of 0.04.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, topping the consensus estimate of ($3.59) by $0.52. The company had revenue of $167.00 million for the quarter, compared to analyst estimates of $93.26 million. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The firm’s revenue was down 91.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.19 earnings per share. As a group, sell-side analysts predict that Moderna, Inc. will post -7.46 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of MRNA. Raymond James Financial Services Advisors Inc. increased its holdings in shares of Moderna by 2.7% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 58,338 shares of the company’s stock valued at $5,802,000 after purchasing an additional 1,554 shares during the period. SeaCrest Wealth Management LLC boosted its stake in shares of Moderna by 40.1% in the fourth quarter. SeaCrest Wealth Management LLC now owns 6,969 shares of the company’s stock valued at $693,000 after buying an additional 1,993 shares in the last quarter. Global Retirement Partners LLC boosted its stake in shares of Moderna by 11.4% in the fourth quarter. Global Retirement Partners LLC now owns 3,184 shares of the company’s stock valued at $325,000 after buying an additional 327 shares in the last quarter. Woodmont Investment Counsel LLC boosted its stake in shares of Moderna by 62.0% in the fourth quarter. Woodmont Investment Counsel LLC now owns 15,066 shares of the company’s stock valued at $1,498,000 after buying an additional 5,766 shares in the last quarter. Finally, ICICI Prudential Asset Management Co Ltd boosted its stake in shares of Moderna by 9.3% in the fourth quarter. ICICI Prudential Asset Management Co Ltd now owns 3,700 shares of the company’s stock valued at $368,000 after buying an additional 314 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on MRNA. William Blair reiterated a “market perform” rating on shares of Moderna in a research note on Thursday, June 27th. Jefferies Financial Group reiterated a “buy” rating and issued a $125.00 price objective on shares of Moderna in a research note on Tuesday, April 9th. Evercore ISI reiterated an “in-line” rating and issued a $120.00 price objective on shares of Moderna in a research note on Thursday, June 27th. Oppenheimer raised their target price on Moderna from $163.00 to $179.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 12th. Finally, Piper Sandler reissued an “overweight” rating and set a $214.00 target price on shares of Moderna in a research report on Thursday, June 27th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, Moderna presently has a consensus rating of “Hold” and an average price target of $133.88.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.